Nanomedicine in lung cancer: Current states of overcoming drug resistance and improving cancer immunotherapy

• Published in: Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology Vol. 13; no. 1; pp. e1654 - n/a
• Main Authors: Wang, Wei, Hao, Yuhao, Liu, Yusheng, Li, Rui, Huang, Da‐Bing, Pan, Yue‐Yin
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01-01-2021; Wiley Subscription Services, Inc
• Subjects: Biocompatibility; Cancer immunotherapy; Cancer therapies; Chemotherapy; Drug delivery systems; Drug resistance; Health services; Immunotherapy; Liposomes; Lung cancer; Metastases; nanomedicine; Nanoparticles; Nanotechnology; Polymers; Side effects; Surgery
• ISSN: 1939-5116; 1939-0041
• DOI: 10.1002/wnan.1654

Lung cancer is considered to cause the most cancer‐related deaths worldwide. Due to the deficiency in early‐stage diagnostics and local invasion or distant metastasis, the first line of treatment for most patients unsuitable for surgery is chemotherapy, targeted therapy or immunotherapy. Nanocarriers with the function of improving drug solubility, in vivo stability, drug distribution in the body, and sustained and targeted delivery, can effectively improve the effect of drug treatment and reduce toxic and side effects, and have been used in clinical treatment for lung cancer and many types of cancers. Here, we review nanoparticle (NP) formulation for lung cancer treatment including liposomes, polymers, and inorganic NPs via systemic and inhaled administration, and highlight the works of overcoming drug resistance and improving cancer immunotherapy.
This article is categorized under:
Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Schematic of nanomedicine with cargoes inside and stabilizer or targeting ligand on surface for lung cancer treatment via inhaled or systemic administration.